Patents by Inventor Sven Jacobson
Sven Jacobson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11311553Abstract: The present invention relates to the treatment patient with a 4-repeat (4R) tauopathy using a therapeutically effect amount of a rho kinase inhibitor. One preferred inhibitor is fasudil and preferred methods involve the daily oral administration of between 20 and 250 mg of fasudil. Preferred 4R tauopathies treatable according to the invention include progressive supranuclear palsy with Richardson syndrome (PSP-RS) and corticobasal syndrome with probable sporadic corticobasal degeneration.Type: GrantFiled: January 8, 2021Date of Patent: April 26, 2022Assignee: WOOLSEY PHARMACEUTICALS, INC.Inventors: Thomas MacAllister, Sven Jacobson
-
Patent number: 11304963Abstract: A method of treating or preventing adverse outcomes associated with tissue plasminogen activator (tPA) administration, cerebral edema-related side effects, cerebral edema associated with radiation therapy, or migraine headaches by administering an effective amount of a SUR1-TRPM4 channel inhibitor, such as glyburide, and optionally the co-administration of a second therapeutically active agent, to a subject in need thereof. Adverse outcomes associated with tPA include cerebral hemorrhage, cerebral edema, physical impairment or death. The administration of the SUR1-TRPM4 channel inhibitors occurs prior to the radiation therapy, during the radiation therapy, after the radiation therapy, or combinations thereof. The SUR1-TRPM4 channel inhibitor is administered prior to surgical excision of a brain tumor, CAR-T therapy, or administration of flutarabine. Alternatively, or in addition, the SUR1-TRPM4 channel inhibitor is administered prior the onset of the cerebral edema-related side effects.Type: GrantFiled: July 28, 2017Date of Patent: April 19, 2022Assignee: Biogen Chesapeake LLCInventors: Sven Jacobson, Thomas Macallister
-
Publication number: 20220088039Abstract: A method of treating or preventing adverse outcomes associated with tissue plasminogen activator (tPA) administration, cerebral edema-related side effects, cerebral edema associated with radiation therapy, or migraine headaches by administering an effective amount of a SUR1-TRPM4 channel inhibitor, such as glyburide, and optionally the co-administration of a second therapeutically active agent, to a subject in need thereof. Adverse outcomes associated with tPA include cerebral hemorrhage, cerebral edema, physical impairment or death. The administration of the SUR1-TRPM4 channel inhibitors occurs prior to the radiation therapy, during the radiation therapy, after the radiation therapy, or combinations thereof. The SUR1-TRPM4 channel inhibitor is administered prior to surgical excision of a brain tumor, CAR-T therapy, or administration of flutarabine. Alternatively, or in addition, the SUR1-TRPM4 channel inhibitor is administered prior the onset of the cerebral edema-related side effects.Type: ApplicationFiled: December 6, 2021Publication date: March 24, 2022Applicant: BIOGEN CHESAPEAKE LLCInventors: Sven JACOBSON, Thomas MACALLISTER
-
Publication number: 20220047607Abstract: The invention relates to the treatment of neurodevelopmental disorders using an inhibitor of rho kinase. Preferred methods contemplate the treatment of infants and children. Certain embodiments involve treating a neurodevelopmental disorder is caused by defects of metabolism, including defects of amino acid transport or metabolism, acid-base balance, carbohydrate transport or metabolism, metal homeostasis, neurotransmitter metabolism, or fatty acid transport or metabolism. Methods address a variety of conditions caused by changes in the genetic material that affect the structure and/or expression of certain genes. Preferred methods treat Down syndrome, Fragile X syndrome, oligophrenin 1 deficiency, Rett syndrome, autistic disorder, Asperger's syndrome, pervasive developmental disorder not otherwise specified, and other autism spectrum disorders.Type: ApplicationFiled: October 26, 2021Publication date: February 17, 2022Inventors: Thomas MACALLISTER, Sven JACOBSON
-
Publication number: 20210401853Abstract: The invention relates to the treatment of neurodevelopmental disorders using an inhibitor of rho kinase. Preferred methods contemplate the treatment of infants and children. Certain embodiments involve treating a neurodevelopmental disorder is caused by defects of metabolism, including defects of amino acid transport or metabolism, acid-base balance, carbohydrate transport or metabolism, metal homeostasis, neurotransmitter metabolism, or fatty acid transport or metabolism. Methods address a variety of conditions caused by changes in the genetic material that affect the structure and/or expression of certain genes. Preferred methods treat Down syndrome, Fragile X syndrome, oligophrenin 1 deficiency, Rett syndrome, autistic disorder, Asperger's syndrome, pervasive developmental disorder not otherwise specified, and other autism spectrum disorders.Type: ApplicationFiled: February 3, 2021Publication date: December 30, 2021Inventors: Thomas MACALLISTER, Sven JACOBSON
-
Publication number: 20210299140Abstract: The invention is based on the discovery that rho kinase inhibitors can be used to treat proteinopathy associated wandering. A number of degenerative neurological diseases are thought to be caused, at least in part, by the formation of protein aggregates that cause neurotoxicity and progressive decline in function. The inventive methods related to the use of rho kinase inhibitors in the treatment of patients with proteinopathy-associated wandering. The patients may be suffering from Huntington's disease, a traumatic brain injury, autism spectrum disorder, Down syndrome or a proteinopathy-associated dementia, such as Alzheimer disease or frontotemporal dementia.Type: ApplicationFiled: January 8, 2021Publication date: September 30, 2021Inventors: Thomas MACALLISTER, Sven JACOBSON
-
Publication number: 20210251943Abstract: The invention relates to the treatment of ascites, and especially refractory ascites, with an orally bioavailable prodrug of dopamine. A preferred prodrug of dopamine is docarpamine. In one embodiment treated patients are, prior to treatment, on doses of furosemide >80 mg/day and/or spironolactone >100 mg/day or equivalent doses of an alternative loop-acting and/or distal-acting diuretic. The ascites treated by the invention are typically caused by liver cirrhosis due to alcohol or non-alcoholic fatty liver disease and generally not due to viral hepatitis or primary biliary cholangitis. Typical patients have an activated renin-angiotensin-aldosterone levels as may be indicated by elevated levels of renin and/or aldosterone. Refractory ascites treatable according to the invention are such that patients beginning treatment require large volume paracentesis at a minimum of: (a) 3 times in 60 days, (b) 4 times in 90 days or (c) at least once every 30 days over a 90-day period.Type: ApplicationFiled: April 29, 2021Publication date: August 19, 2021Inventors: Sven Jacobson, Thomas MacAllister
-
Publication number: 20210255200Abstract: Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.Type: ApplicationFiled: April 27, 2021Publication date: August 19, 2021Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Sven Jacobson
-
Publication number: 20210213030Abstract: The invention is based on the discovery that rho kinase inhibitors can be used to treat certain dementia-associated wandering. The inventive methods relate to the use of rho kinase inhibitors in the treatment of patients with cortical dementia-associated wandering. Preferred aspects of the invention contemplate treating wandering due to cortical vascular dementia and wandering due to dementia where the patient is a persistent wanderer and/or where the patient does not display a wayfinding defect.Type: ApplicationFiled: January 8, 2021Publication date: July 15, 2021Inventors: Thomas MACALLISTER, Sven JACOBSON
-
Patent number: 11016103Abstract: Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.Type: GrantFiled: August 13, 2018Date of Patent: May 25, 2021Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Sven Jacobson
-
Patent number: 10900040Abstract: Embodiments of the disclosure encompass methods and/or compositions for ameliorating or preventing intimal damage caused by mechanical stimulation of endothelial cells. The damage may be caused by use of a device within an artery, vein, or capillary of an individual, such as to remove a thrombus, an embolus or an atherosclerotic plaque in the vessel. Treatment and prevention embodiments concern therapeutically effective amounts of one or more antagonists of the SUR1-TRPM4 channel that is upregulated upon the mechanical stimulation.Type: GrantFiled: May 25, 2016Date of Patent: January 26, 2021Assignees: University of Maryland, Baltimore, The United States of America as Represented by the Department of Veterans Affairs, Biogen Chesapeake, LLCInventors: J. Marc Simard, Sven Jacobson
-
Publication number: 20200335220Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: ApplicationFiled: July 7, 2020Publication date: October 22, 2020Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien, Sven Jacobson
-
Patent number: 10741290Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: GrantFiled: April 10, 2019Date of Patent: August 11, 2020Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien, Sven Jacobson
-
Patent number: 10688111Abstract: The invention provides liquid formulations of compounds that act at sulfonylurea receptors that are suitable for intravenous and intra-arterial infusion. Compounds active at a sulfonylurea receptor include glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, and glimepiride. Liquid formulations may be concentrated solutions suitable for storage; may be diluted (e.g., dilution of 1:1 or 1:1.2) suitable for bolus injections, and may be further diluted (e.g., dilution of 1:10 or 1:20 or more) for intravenous and intra-arterial infusion over an extended period of time. For example, a liquid formulation may include at least about 0.05 mg/ml glibenclamide in a water-based solution including 40% polyethylene glycol 300, 10% Ethanol, 50% water, at about pH 9. The solution may include a buffer, and is suitable for storage in refrigerator or at room temperature. This solution may be diluted 1:1, or more (e.g., 1:20) without precipitation of the glibenclamide.Type: GrantFiled: April 8, 2016Date of Patent: June 23, 2020Assignee: Biogen Chesapeake LLCInventors: Sven Jacobson, Gillian Clarke, Rajinder Matharu
-
Publication number: 20190237197Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: ApplicationFiled: April 10, 2019Publication date: August 1, 2019Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien, Sven Jacobson
-
Publication number: 20190175624Abstract: A method of treating or preventing adverse outcomes associated with tissue plasminogen activator (tPA) administration, cerebral edema-related side effects, cerebral edema associated with radiation therapy, or migraine headaches by administering an effective amount of a SUR1-TRPM4 channel inhibitor, such as glyburide, and optionally the co-administration of a second therapeutically active agent, to a subject in need thereof. Adverse outcomes associated with tPA include cerebral hemorrhage, cerebral edema, physical impairment or death. The administration of the SUR1-TRPM4 channel inhibitors occurs prior to the radiation therapy, during the radiation therapy, after the radiation therapy, or combinations thereof. The SUR1-TRPM4 channel inhibitor is administered prior to surgical excision of a brain tumor, CAR-T therapy, or administration of flutarabine. Alternatively, or in addition, the SUR1-TRPM4 channel inhibitor is administered prior the onset of the cerebral edema-related side effects.Type: ApplicationFiled: July 28, 2017Publication date: June 13, 2019Applicant: BIOGEN CHESAPEAKE LLCInventors: Sven JACOBSON, Thomas MACALLISTER
-
Publication number: 20190167611Abstract: A method of treating or preventing amyloid related imaging abnormalities (ARIA) in patients receiving one or more course of medical treatment for Alzheimer's Disease includes administrating a SUR1-TRPM4 channel inhibitor, such as glyburide, in an amount effective to prevent the formation or reduce the size of one or more ARIAs in the brain.Type: ApplicationFiled: July 28, 2017Publication date: June 6, 2019Applicant: BIOGEN CHESAPEAKE LLCInventors: Sven JACOBSON, Thomas MACALLISTER
-
Patent number: 10303844Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: GrantFiled: December 20, 2016Date of Patent: May 28, 2019Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien, Sven Jacobson
-
Publication number: 20190120852Abstract: This invention relates to methods for the detection of cardiovascular disease, e.g., acute coronary syndrome, heart failure and/or pulmonary embolism, in high body mass index (BMI) individuals, e.g., with a BMI of 25-29, or 30 or above, and those with impaired renal function.Type: ApplicationFiled: December 17, 2018Publication date: April 25, 2019Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Sven Jacobson
-
Patent number: 10203339Abstract: This invention relates to methods for the detection of cardiovascular disease, e.g., acute coronary syndrome, heart failure and/or pulmonary embolism, in high body mass index (BMI) individuals, e.g., with a BMI of 25-29, or 30 or above, and those with impaired renal function.Type: GrantFiled: May 1, 2007Date of Patent: February 12, 2019Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Sven Jacobson